{"id":"sacituzumab-govitecan-sg","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of a humanized monoclonal antibody against Trop-2 (a tumor-associated antigen) conjugated to govitecan, which is metabolized to SN-38, a potent topoisomerase I inhibitor. Upon binding to Trop-2 on cancer cell surfaces, the antibody-drug conjugate is internalized, releasing SN-38 intracellularly to induce DNA damage and apoptosis. This targeted delivery approach aims to maximize efficacy while reducing systemic toxicity compared to unconjugated chemotherapy.","oneSentence":"Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2 on cancer cells and delivers the topoisomerase I inhibitor SN-38 directly to tumor tissue.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:07.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic triple-negative breast cancer"},{"name":"Metastatic urothelial carcinoma"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07328490","phase":"PHASE1, PHASE2","title":"Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma","enrollment":120},{"nctId":"NCT07438600","phase":"PHASE2","title":"Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-24","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":38},{"nctId":"NCT06801834","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-04-04","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":695},{"nctId":"NCT05633667","phase":"PHASE2","title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-03-16","conditions":"Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer","enrollment":270},{"nctId":"NCT03547973","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2018-08-13","conditions":"Metastatic Urothelial Cancer","enrollment":827},{"nctId":"NCT05833867","phase":"PHASE1","title":"Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Shilpa Gupta, MD","startDate":"2024-04-01","conditions":"Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma","enrollment":20},{"nctId":"NCT07063212","phase":"PHASE2","title":"A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-07-02","conditions":"Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer","enrollment":40},{"nctId":"NCT06963905","phase":"PHASE1, PHASE2","title":"Saci Nivo Rela for TNBC","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-29","conditions":"Metastatic Triple-negative Breast Cancer","enrollment":60},{"nctId":"NCT05186974","phase":"PHASE2","title":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-05-30","conditions":"Non-small Cell Lung Cancer","enrollment":193},{"nctId":"NCT06926920","phase":"PHASE1, PHASE2","title":"A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-04-30","conditions":"Triple Negative Breast Cancer","enrollment":100},{"nctId":"NCT03964727","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-10-15","conditions":"Metastatic Solid Tumor","enrollment":223},{"nctId":"NCT07339059","phase":"PHASE2","title":"SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer","status":"RECRUITING","sponsor":"Bindu R Potugari","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":35},{"nctId":"NCT07367178","phase":"PHASE2","title":"Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07","conditions":"Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Triple-Negative Breast Cancer","enrollment":30},{"nctId":"NCT07368543","phase":"PHASE2","title":"Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-16","conditions":"Metastatic Breast Cancer","enrollment":216},{"nctId":"NCT07134556","phase":"PHASE2","title":"Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-03","conditions":"Triple Negative Breast Cancer, PDL-1 Positive","enrollment":25},{"nctId":"NCT03869190","phase":"PHASE1, PHASE2","title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-01","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":272},{"nctId":"NCT07359404","phase":"PHASE2","title":"Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC","status":"ENROLLING_BY_INVITATION","sponsor":"YING FAN","startDate":"2024-04-01","conditions":"Advanced Breast Cancer","enrollment":60},{"nctId":"NCT06865677","phase":"PHASE2","title":"Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-09","conditions":"Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma","enrollment":2},{"nctId":"NCT05633654","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-12-12","conditions":"Triple Negative Breast Cancer","enrollment":1514},{"nctId":"NCT06486441","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-28","conditions":"Endometrial Cancer","enrollment":640},{"nctId":"NCT06263543","phase":"PHASE2","title":"Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC","status":"RECRUITING","sponsor":"Reshma L. Mahtani, D.O.","startDate":"2024-06-17","conditions":"Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":75},{"nctId":"NCT07299409","phase":"PHASE2","title":"First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.","status":"NOT_YET_RECRUITING","sponsor":"Nathalie Levasseur","startDate":"2025-12","conditions":"Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic, Breast Cancer","enrollment":24},{"nctId":"NCT04863885","phase":"PHASE1, PHASE2","title":"Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-04-30","conditions":"Metastatic Urothelial Carcinoma","enrollment":46},{"nctId":"NCT07271992","phase":"PHASE2","title":"TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2025-12-15","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT06238921","phase":"PHASE1, PHASE2","title":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-12-19","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":31},{"nctId":"NCT07259226","phase":"PHASE2","title":"Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer","enrollment":400},{"nctId":"NCT07251868","phase":"","title":"Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-08-01","conditions":"Breast Cancer, Brain Metastases From Breast Cancer, Trop2","enrollment":100},{"nctId":"NCT06081244","phase":"PHASE3","title":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","status":"RECRUITING","sponsor":"West German Study Group","startDate":"2024-10-10","conditions":"Triple Negative Breast Cancer","enrollment":348},{"nctId":"NCT05119907","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-10-12","conditions":"Solid Tumor","enrollment":53},{"nctId":"NCT04794699","phase":"PHASE1","title":"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion","status":"RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2021-04-14","conditions":"Solid Tumor","enrollment":180},{"nctId":"NCT04724018","phase":"PHASE1, PHASE2","title":"Sacituzumab Govitecan Plus EV in Metastatic UC","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-05-20","conditions":"Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter","enrollment":106},{"nctId":"NCT05840211","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-08","conditions":"Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer","enrollment":654},{"nctId":"NCT04319198","phase":"PHASE4","title":"Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-08-04","conditions":"Metastatic Solid Tumors","enrollment":25},{"nctId":"NCT06827613","phase":"PHASE1, PHASE2","title":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Marengo Therapeutics, Inc.","startDate":"2025-03-24","conditions":"Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":50},{"nctId":"NCT05382286","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-07-25","conditions":"Triple Negative Breast Cancer, PD-L1 Positive","enrollment":443},{"nctId":"NCT07178730","phase":"PHASE3","title":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West German Study Group","startDate":"2026-01-31","conditions":"Breast Cancer, Triple-negative Breast Cancer","enrollment":765},{"nctId":"NCT07040644","phase":"PHASE2","title":"A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-09","conditions":"Triple Negative Breast Neoplasms","enrollment":150},{"nctId":"NCT05382299","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-07-20","conditions":"Triple Negative Breast Cancer, PD-L1 Negative","enrollment":623},{"nctId":"NCT07151586","phase":"PHASE2","title":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2025-10","conditions":"Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer","enrollment":260},{"nctId":"NCT06616987","phase":"PHASE2","title":"Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Yeon Hee Park","startDate":"2025-07-03","conditions":"Breast Cancer Metastatic","enrollment":40},{"nctId":"NCT06923826","phase":"PHASE2","title":"Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-04-15","conditions":"Salivary Gland Cancer, Thyroid Cancer","enrollment":32},{"nctId":"NCT04381832","phase":"PHASE1, PHASE2","title":"Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Arcus Biosciences, Inc.","startDate":"2020-07-07","conditions":"Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms","enrollment":173},{"nctId":"NCT06477419","phase":"PHASE2","title":"A Study of Sacituzumab Govitecan in People With Mesothelioma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-06-21","conditions":"Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura","enrollment":33},{"nctId":"NCT07046455","phase":"NA","title":"Trop-2 Targeted PET Probes in Advanced TNBC","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-03-01","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":20},{"nctId":"NCT06665178","phase":"PHASE2","title":"Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer","status":"RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2025-03-31","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT07018427","phase":"","title":"Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-05-01","conditions":"Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":70},{"nctId":"NCT05552001","phase":"PHASE3","title":"Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-10-05","conditions":"Triple Negative Breast Cancer, Metastatic Breast Cancer","enrollment":96},{"nctId":"NCT06991790","phase":"","title":"Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-05-01","conditions":"TNBC","enrollment":51},{"nctId":"NCT05089734","phase":"PHASE3","title":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-11-17","conditions":"Non-Small Cell Lung Cancer","enrollment":603},{"nctId":"NCT06055465","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-02-28","conditions":"Lung Cancer","enrollment":37},{"nctId":"NCT06966141","phase":"","title":"A Real World Study of Sacituzumab Govitecan","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-08-12","conditions":"Breast Cancer Metastatic, Treatment Outcome","enrollment":100},{"nctId":"NCT06401824","phase":"PHASE2","title":"Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2025-04-24","conditions":"NSCLC Stage IV, Brain Metastases, Adult","enrollment":25},{"nctId":"NCT06431633","phase":"PHASE3","title":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2025-02-04","conditions":"Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma","enrollment":129},{"nctId":"NCT06682728","phase":"PHASE2","title":"Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2024-11-15","conditions":"Urothelial Carcinoma, Muscle-invasive Bladder Cancer","enrollment":23},{"nctId":"NCT05101096","phase":"PHASE1, PHASE2","title":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-10-20","conditions":"Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer","enrollment":135},{"nctId":"NCT06167317","phase":"PHASE1","title":"Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-01-09","conditions":"Advanced Solid Tumors","enrollment":254},{"nctId":"NCT06243393","phase":"PHASE2, PHASE3","title":"Sacituzumab Govitecan in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University Hospital Heidelberg","startDate":"2024-04-19","conditions":"Metastatic Colorectal Cancer","enrollment":80},{"nctId":"NCT06341478","phase":"NA","title":"Investigator Grant (IG) 2022 27746","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2024-03-15","conditions":"Bladder Cancer","enrollment":153},{"nctId":"NCT06328387","phase":"PHASE1, PHASE2","title":"HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-01-29","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT05708144","phase":"NA","title":"NIR Fluorescent Molecular Probe for the Identification of Breast Tissue","status":"COMPLETED","sponsor":"Xiang'an Hospital of Xiamen University","startDate":"2023-02-17","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT01631552","phase":"PHASE1, PHASE2","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-12-17","conditions":"Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma","enrollment":515}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trodelvy®","GS-0132","IMMU 132","Trodelvy","IMMU-132"],"phase":"phase_3","status":"active","brandName":"Sacituzumab Govitecan (SG)","genericName":"Sacituzumab Govitecan (SG)","companyName":"University of California, Irvine","companyId":"university-of-california-irvine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2 on cancer cells and delivers the topoisomerase I inhibitor SN-38 directly to tumor tissue. Used for Metastatic triple-negative breast cancer, Metastatic urothelial carcinoma, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}